IMAGENEBIO INC

IMANASDAQ

🏆 #3960 by market capEarnings Nov 11US Equity

$5.73▲ $0.12 (+2.14%)

Live

1h—

24h▲ 2.1%

7d▲ 0.5%

14d▼ 0.9%

30d▼ 3.3%

1y▼ 60.5%

🏦Market Cap

$65M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

7.0x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $5.66 – $5.84
52-Week Range: $3.94 – $15.79
Volume: $2.70B
Avg Volume: $2.60B
Shares Outstanding: 11.3M
Next Earnings: Sep 29, 2026

Fundamentals Snapshot

Annual Revenue: $800,000
Last Q Revenue: $184,753
P/E Ratio: —
P/S Ratio: 7.0x
EPS (TTM): $-5.40
Dividend Yield: —

Why Investors Own IMA

✓High-growth profile — revenue up +30.6% YoY with expanding US Equity exposure.
✓Healthy economics — 70% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$800,000▲ +31.9% YoY

Gross Margin (TTM)

70.2%▲ +2.1% YoY

Operating Income (TTM)

$196,800▲ +31.9% YoY

Free Cash Flow (TTM)

$204,800▲ +31.9% YoY

About IMAGENEBIO INC

ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.

🦦